Faculty Bibliography

Hepatitis B reactivation can occur with cytotoxic chemotherapy in patients with hepatitis B and cancer. Reactivation can occur in a patient with chronic hepatitis, an inactive carrier, or one with resolved hepatitis. Clinical presentation may range from subclinical elevation of liver enzymes to fatal fulminant hepatic failure. Mammalian target of rapamycin inhibitors, which include everolimus, are a new generation of targeted agents that are currently approved for many cancers (since March 2009) including advanced hormone receptor positive, human epidermal growth factor receptor 2-negative breast cancer, in conjunction with exemestane (as of July 2012). We are therefore still learning the various adverse events that occur with this new class of agents. Here, we present an unfortunate case of fatal hepatitis B reactivation in a woman with metastatic breast cancer treated with everolimus and exemestane. We have detailed the controversies around hepatitis B screening prior to immunosuppressive therapy. Clinicians and patients should be aware of this rare but fatal complication prior to everolimus use, and a detailed history, screening for hepatitis B and prophylactic antiviral treatment should be considered.

Purpose:To assess diagnostic sensitivity of radial T1-weighted gradient-echo (radial volumetric interpolated breath-hold examination [VIBE]) magnetic resonance (MR) imaging, positron emission tomography (PET), and combined simultaneous PET and MR imaging with an integrated PET/MR system in the detection of lung nodules, with combined PET and computed tomography (CT) as a reference.Materials and Methods:In this institutional review board-approved HIPAA-compliant prospective study, 32 patients with tumors who underwent clinically warranted fluorine 18 (18F) fluorodeoxyglucose (FDG) PET/CT followed by PET/MR imaging were included. In all patients, the thorax station was examined with free-breathing radial VIBE MR imaging and simultaneously acquired PET data. Presence and size of nodules and FDG avidity were assessed on PET/CT, radial VIBE, PET, and PET/MR images. Percentage of nodules detected on radial VIBE and PET images was compared with that on PET/MR images by using generalized estimating equations. Maximum standardized uptake value (SUVmax) in pulmonary nodules with a diameter of at least 1 cm was compared between PET/CT and PET/MR imaging with Pearson rank correlation.Results:A total of 69 nodules, including 45 FDG-avid nodules, were detected with PET/CT. The sensitivity of PET/MR imaging was 70.3% for all nodules, 95.6% for FDG-avid nodules, and 88.6% for nodules 0.5 cm in diameter or larger. PET/MR imaging had higher sensitivity than PET for all nodules (70.3% vs 61.6%, P = .002) and higher sensitivity than MR imaging for FDG-avid nodules (95.6% vs 80.0%, P = .008). There was a significantly strong correlation between SUVmax of pulmonary nodules obtained with PET/CT and that obtained with PET/MR imaging (r = 0.96, P < .001).Conclusion:Radial VIBE and PET data acquired simultaneously with PET/MR imaging have high sensitivity in the detection of FDG-avid nodules and nodules 0.5 cm in diameter or larger, with low sensitivity for small non-FDG-avid nodules.(c) RSNA, 2013.

INTRODUCTION: Accurate, reproducible acquisition and interpretation of PET-CT scans can be challenging. As part of an annual quality enhancement exercise for Nuclear Medicine laboratories in the US Department of Veterans Affairs (DVA), we employed a chest imaging phantom designed to test integrated PET-CT imaging and interpretative performance. METHODS: In late 2011, a PET-CT chest phantom was imaged by 88 PET/PET-CT scanners. The phantom, developed by the SNM Quality Assurance Committee (QAC) simulated a stage IIIb lung cancer with 2 "malignant" lung nodules and 3 "metastatic" lymph nodes. Data collection included DICOM images, quality control information, scanner type, imaging parameters (PET and CT) and dose-calibrator information. Interpreting physicians (N=180) reported lesion locations, body-weight-corrected SUVmax and "staged" the simulated lung cancer. We analyzed factors associated with poor performance to assist with remediation of problems identified with image acquisition, processing and interpretation. RESULTS: Based upon QAC-established performance benchmarks 16% (n=14) laboratories failed the exercise. Suboptimal image quality was most often related to short acquisition times (n=6, 6.8%) e.g. 2D mode scanners with imaging time/bed position <3min; suboptimal reconstruction parameters (n=6, 6.8%) e.g. filtered back projection rather than iterative reconstruction; outdated scanners (n=3, 3.4%) e.g. >8y/o without integrated CT; and data entry errors (n=2, 2.3%). SUVmax values varied due to several errors e.g. improper calibration factors or calculation/s. 5% failures (n=4) were related to protocol non-adherence. 33 sites (38%) had not updated dose-calibrators to conform to new NIST standards. 4 sites (5%) used CT tube electrical currents >240 mA for "non-diagnostic" CT. Interpretative performance was negatively impacted by incorrect lesion detection/localization and/or SUV calculations/interpretation. 45 (25%) physicians did not assign Stage IIIb, indicating lack of knowledge of contemporary criteria for lung cancer staging. Other important errors included knowledge of the glucose effect on SUV (n=16, 9% incorrect) and dependence of SUVmean calculations on thresholding techniques (n=38, 21% incorrect). CONCLUSIONS: These "lessons learned" have been used to remediate poor performance and to improve and standardize PET-CT imaging and interpretation in DVA. Our >20yr experience with simulated imaging phantoms continues to demonstrate that strict adherence to standardized NM procedure guidelines is critical for optimal image quality, correct interpretation, longitudinal parametric data comparisons and meaningful participation in clinical trials

Background: Interpreting I-131 whole-body scans (WBSs) after thyroidectomy for thyroid cancer is not simple. There are scans in which interpretation is speculative because of cryptic findings (CF). Complexity is added in scans that are done a week after an ablative or therapeutic dose of I-131 because not only is I-131-labeled thyroxine (T4) distributed throughout the body, but inorganic I-131 that is derived from the de-iodination of T4 may be also detected. We present our observations regarding the analysis of CF on WBS using I-131 single-photon emission computed tomography (SPECT) in fusion with noncontrast computed tomography (CT), referred to here and elsewhere as I-131 SPECT/CT. Methods: Forty of 184 WBSs in 38 thyroidectomized thyroid cancer patients were followed up with I-131 SPECT/CTs. The SPECT/CT images were acquired after a tracer dose of I-131 (n=82) or a week after an ablative or therapeutic dose of I-131 (n=102). Results: Among 184 WBSs, 40 (22%) had CF. In 35 patients the WBS was negative for metastatic disease except for the CF and 5 patients had evidence of thyroid cancer in addition to the CF. There were 49 CF in the planar scans that were localized by SPECT/CT. These were characterized as physiological uptake in gingiva, thymus, gall bladder, menstrual blood, uterine fibroid, recto-sigmoid, colon, and bladder. Also observed was uptake in sites that represented nonthyroidal pathology including dental abscess, hiatal hernia, renal cyst, and struma ovarii. SPECT/CT suggested that 10 of the CF were actually of thyroid origin. In 40 SPECT/CT scans, the images contributed to interpreting the scan. In 15 of 40 patients the SPECT/CT analysis of WBS was performed with tracer doses of I-131 and was important for determining whether to administer ablative I-131 treatment. In another 25 patients, in whom SPECT/CT was performed after ablative or therapeutic doses of 131-I, information regarding the characterization of CF by SPECT/CT was useful in determining if thyroid cancer metastases or thyroid remnants were present. Conclusions: I-131 SPECT/CT is a useful tool to characterize atypical or CF on WBS by differentiating thyroid remnant or cancer from physiologic activity or nonthyroid pathology. In the past, uptake on a WBS that was not explicable as physiologic activity was identified as putative or possible thyroid cancer and generally was treated with I-131. Now, by identifying activity in some possible cancer sites as not thyroid cancer, SPECT/CT can reduce inappropriate treatment with I-131. SPECT/CT of WBS performed after ablative doses of 131-I is useful in determining the nature of CF and therefore likely providing prognostic information

Background: Occasionally, blood samples may be required from thyroid cancer patients after they have been given the therapy dose of (131)I, as part of necessary medical management of comorbidities. Thus, in the days after (131)I administration, medical health professionals may be involved in the withdrawal, handling, and manipulation of radioactive blood samples. The purpose of this study was to quantify the amount of radioactivity in blood samples taken from thyroidectomized thyroid carcinoma patients after the administration of therapeutic activities of (131)I. Methods: For dosimetry purposes, serial blood sampling is performed on thyroidectomized thyroid carcinoma patients prior to therapy with (131)I. The quantities of radioactive material present in these blood samples were expressed as a percentage of the administered activity and then extrapolated to the high levels of (131)I used in therapy for 377 patients in this study. The corresponding radiation exposure rate from the blood samples was then calculated to determine what radiation protection methods were required for staff handling these samples. Results: The average amount of radioactivity in a 1 mL blood sample at 1 hour postadministration of 5.5 GBq (150 mCi) of (131)I was 0.2 +/- 0.15 MBq (5.4 +/- 4.0 muCi). This corresponds to an exposure rate of 1.23 muSv/h (0.123 mrem/h) at 10 cm from the sample. For samples obtained beyond 24 hours after a therapeutic administration of 5.55 GBq (150 mCi), the exposure levels are approximately equal to background radiation. Conclusion: The data in this study indicate that the radiation exposure from blood samples withdrawn from thyroidectomized thyroid cancer patients is low. However, to ensure that staff members are exposed to minimal levels of radiation, it is imperative that staff members who are involved in withdrawing, handling, or manipulating radioactive blood samples adhere to the recommended radiation safety practices